CYP2C19 allele linked with increased risk for major adverse CV events in patients given clopidogrel for PCI

December 2010
Hem/Onc Today;12/25/2010, Vol. 11 Issue 24, p35
The article discusses a study which revealed the association of CYP2C19 allele with increased risk for major adverse cardiovascular events in patients given clopidogrel for percutaneous coronary intervention.


Related Articles

  • Attenuated CV Benefits of Clopidogrel in Diabetes. Kuritzky, Louis // Internal Medicine Alert;10/29/2012 Clinical Briefs, p160 

    The article discusses the benefits of the antiplatelet therapy using clopidogrel in the reduction of cardiovascular risks among diabetes and non diabetes patients.

  • Attenuated CV Benefits of Clopidogrel in Diabetes.  // Infectious Disease Alert;Nov2012 Clinical Briefs in Primary Care, p22 

    The article discusses the benefits of using clopidogrel among diabetic patients in terms of reducing cardiovascular events, which according to a study by Andersson and his colleagues favored more non-diabetics like in the hazard ratio for all-cause mortality.

  • Attenuated CV Benefits of Clopidogrel in Diabetes. Kuritzky, Louis // OB/GYN Clinical Alert;Nov2012 Clinical Briefs in Primary Care, p22 

    The article offers information on the role of drugs including clopidogrel and aspirin being used in antiplatelet therapy to reduce the cardiovascular (CV) events in diabetic patients.

  • Effects of Combined Aspirin and Clopidogrel Therapy on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Yu-Hao Zhou; Xin Wei; Jian Lu; Xiao-Fei Ye; Mei-Jing Wu; Jin-Fang Xu; Ying-Yi Qin; Jia He // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Background: Aspirin and clopidogrel monotherapies are effective treatments for preventing vascular disease. However, new evidence has emerged regarding the use of combined aspirin and clopidogrel therapy to prevent cardiovascular events. We therefore performed a comprehensive systematic review...

  • Ticagrelor was more effective than clopidogrel, with no increase in major bleeding in acute coronary syndromes. Bates, Eric R. // ACP Journal Club;12/15/2009, Vol. 151 Issue 6, p2 

    The article presents information on a clinical trial which examines the relative efficacy and safety of ticagrelor and clopidogrel in patients with acute coronary syndromes (ACSs). 18,624 patients of 18 years were selected from 862 centers in 43 countries worldwide. The results show that in...

  • Detection of clopidogrel resistance by MEA and LTA. Slavik, L.; Ulehlova, J.; Krcova, V.; Hlusi, A.; Indrakova, J.; Hutyra, M.; Galuszka, J.; Indrak, K. // Transfusiology & Haematology Today / Transfuze a Hematologie Dne;Jun2011, Vol. 17 Issue 2, p92 

    Antiaggregation therapy is still the most frequently used approach to prevent thrombotic events in cardiovascular disease. It has a good clinical effect but there is increasing evidence of high residual platelet aggregation activity in a number of patients. Laboratory methods only allow us to...

  • A message from Dr. Kereiakes. Kereiakes, Dean J. // Cincinnati Magazine;Jun2010, Vol. 43 Issue 9, Special Section p2 

    The article reports on the new developments in the treatment of cradivascular disease. One of the medications is clopidogrel, a blood-thinner which is prescribed to reduce the possibility of heart attack, stroke and death. It reports that when combined with aspirin, clopidogrel reduces the...

  • Clopidogrel for Two Years after Drug-eluting Stents? Boyle, Andrew J. // Clinical Cardiology Alert;Jan2010, Vol. 29 Issue 1, p1 

    The article discusses research on the efficacy of two-year clopidogrel combined with aspirin in eliminating the risk of very late thrombosis following drug-eluting stent implantation. It references a prospective registry study by G. Tanzilli et al, published in a 2009 issue of the "American...

  • The P450 system and CV outcomes with clopidogrel. Kuritzky, Louis // Neurology Alert;Jan2011 Primary Care, Vol. 16 Issue 1, p1 

    The article discusses research on the clinical relevance of the P450 system and efficacy of clopidogrel in cardiovascular outcomes, referencing a study by G. Pare et al published in a 2010 issue of the "New England Journal of Medicine."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics